Obtaining consistent results across two RNA silencing modalities targeting different homologous HTT/Htt sequences suggests that the weaker silencing in GBM cells is likely not related to the oligonucleotide sequence or effector (RNase H or Ago) activity. The gene discussed is HTT; the disease is glioblastoma.